tiprankstipranks
Crispr Therapeutics (CRSP)
NASDAQ:CRSP
US Market
CRSP
Crispr Therapeutics AG
RESEARCH TOOLSreports
Want to see CRSP full AI Analyst Report?

Crispr Therapeutics AG (CRSP) Stock Forecast & Price Target

11,004 Followers
See the Price Targets and Ratings of:

CRSP Analyst Ratings

Moderate Buy
15Ratings
Moderate Buy
9 Buy
6 Hold
0 Sell
Based on 15 analysts giving stock ratings to
Crispr
Therapeutics AG
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CRSP Stock 12 Month Forecast

Average Price Target

$73.14
▲(57.16% Upside)
Based on 15 Wall Street analysts offering 12 month price targets for Crispr Therapeutics AG in the last 3 months. The average price target is $73.14 with a high forecast of $110.00 and a low forecast of $45.00. The average price target represents a 57.16% change from the last price of $46.54.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"44":"$44","111":"$111","60.75":"$60.8","77.5":"$77.5","94.25":"$94.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":110,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$110.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":73.14285714285714,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$73.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$45.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[44,60.75,77.5,94.25,111],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.99,52.760000000000005,57.53,62.3,67.07,71.84,76.61,81.38,86.15,90.91999999999999,95.69,100.46000000000001,105.22999999999999,{"y":110,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.99,49.924835164835166,51.85967032967033,53.79450549450549,55.72934065934066,57.66417582417582,59.59901098901099,61.533846153846156,63.46868131868132,65.40351648351648,67.33835164835165,69.27318681318681,71.20802197802197,{"y":73.14285714285714,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.99,47.760000000000005,47.53,47.300000000000004,47.07,46.84,46.61,46.38,46.15,45.92,45.69,45.46,45.230000000000004,{"y":45,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":56.09,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.66,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.16,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.99,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.17,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.44,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.31,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.77,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.81,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.63,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.19,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.62,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.99,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$110.00Average Price Target$73.14Lowest Price Target$45.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on CRSP
Salveen Richter
Goldman Sachs
Goldman Sachs
$48→$55
Hold
18.18%
Upside
Assigned
08/07/26
Goldman Sachs Keeps Their Hold Rating on Crispr Therapeutics AG (CRSP)
Wells Fargo Analyst forecast on CRSP
Yanan Zhu
Wells Fargo
Wells Fargo
$75
Hold
61.15%
Upside
Reiterated
08/05/26
Crispr Therapeutics AG (CRSP) Receives a Hold from Wells Fargo
H.C. Wainwright Analyst forecast on CRSP
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$80
Buy
71.90%
Upside
Reiterated
08/05/26
CRISPR Therapeutics: Buy Rating Reiterated, $80 Price Target Maintained Ahead of Key HORIZON Catalyst
Bank of America Securities Analyst forecast on CRSP
Alec Stranahan
Bank of America Securities
Bank of America Securities
$83→$82
Buy
76.19%
Upside
Reiterated
08/05/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
William Blair Analyst forecast on CRSP
Sami Corwin
William Blair
William Blair
―
Buy
―
Reiterated
08/04/26
Analyst Maintains Buy on CRISPR Therapeutics as Casgevy Ramp and Diversified Pipeline Strengthen Long-Term Growth Outlook
Needham Analyst forecast on CRSP
Gil Blum
Needham
Needham
$82
Buy
76.19%
Upside
Reiterated
08/04/26
Crispr Therapeutics: Strong Casgevy Uptake, Expanding Pipeline and Cash Runway Support Unchanged $82 Price Target and Buy Rating
Morgan Stanley Analyst forecast on CRSP
Terence Flynn
Morgan Stanley
Morgan Stanley
$60
Hold
28.92%
Upside
Reiterated
08/04/26
Morgan Stanley Sticks to Their Hold Rating for Crispr Therapeutics AG (CRSP)
Piper Sandler Analyst forecast on CRSP
Edward Tenthoff
Piper Sandler
Piper Sandler
$110
Buy
136.36%
Upside
Reiterated
08/04/26
Piper Sandler Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)
TD Cowen Analyst forecast on CRSP
Tyler Van Buren
TD Cowen
TD Cowen
$45
Hold
-3.31%
Downside
Reiterated
08/03/26
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (NASDAQ: CRSP), Supernus Pharmaceuticals (NASDAQ: SUPN) and Krystal Biotech (NASDAQ: KRYS)
Citi Analyst forecast on CRSP
Yigal Nochomovitz
Citi
Citi
$82→$88
Buy
89.08%
Upside
Reiterated
08/03/26
Casgevy Momentum and Pipeline Catalysts Drive Yigal Nochomovitz to Maintain Buy Rating and Raise Price Target to $88
RBC Capital Analyst forecast on CRSP
Luca Issi
RBC Capital
RBC Capital
$50
Hold
7.43%
Upside
Reiterated
08/03/26
RBC Capital Keeps Their Hold Rating on Crispr Therapeutics AG (CRSP)
Citizens JMP Analyst forecast on CRSP
Silvan Turkcan
Citizens JMP
Citizens JMP
$80
Buy
71.90%
Upside
Reiterated
07/22/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Crispr Therapeutics AG (NASDAQ: CRSP) and GlaxoSmithKline (LSE: GB:GSK)
Mizuho Securities Analyst forecast on CRSP
Unknown Analyst
Mizuho Securities
Not Ranked
Mizuho Securities
$85
Buy
82.64%
Upside
Reiterated
06/10/26
Crispr Therapeutics AG (CRSP) Gets a Buy from Mizuho Securities
Bernstein Analyst forecast on CRSP
William Pickering
Bernstein
Bernstein
$50→$56
Hold
20.33%
Upside
Assigned
05/13/26
Crispr Therapeutics price target raised to $56 from $50 at BernsteinCrispr Therapeutics price target raised to $56 from $50 at Bernstein
Evercore ISI Analyst forecast on CRSP
Jonathan Miller
Evercore ISI
Evercore ISI
$74→$76
Buy
63.30%
Upside
Reiterated
05/11/26
Crispr Therapeutics price target raised to $76 from $74 at Evercore ISICrispr Therapeutics price target raised to $76 from $74 at Evercore ISI
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on CRSP
Salveen Richter
Goldman Sachs
Goldman Sachs
$48→$55
Hold
18.18%
Upside
Assigned
08/07/26
Goldman Sachs Keeps Their Hold Rating on Crispr Therapeutics AG (CRSP)
Wells Fargo Analyst forecast on CRSP
Yanan Zhu
Wells Fargo
Wells Fargo
$75
Hold
61.15%
Upside
Reiterated
08/05/26
Crispr Therapeutics AG (CRSP) Receives a Hold from Wells Fargo
H.C. Wainwright Analyst forecast on CRSP
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$80
Buy
71.90%
Upside
Reiterated
08/05/26
CRISPR Therapeutics: Buy Rating Reiterated, $80 Price Target Maintained Ahead of Key HORIZON Catalyst
Bank of America Securities Analyst forecast on CRSP
Alec Stranahan
Bank of America Securities
Bank of America Securities
$83→$82
Buy
76.19%
Upside
Reiterated
08/05/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
William Blair Analyst forecast on CRSP
Sami Corwin
William Blair
William Blair
―
Buy
―
Reiterated
08/04/26
Analyst Maintains Buy on CRISPR Therapeutics as Casgevy Ramp and Diversified Pipeline Strengthen Long-Term Growth Outlook
Needham Analyst forecast on CRSP
Gil Blum
Needham
Needham
$82
Buy
76.19%
Upside
Reiterated
08/04/26
Crispr Therapeutics: Strong Casgevy Uptake, Expanding Pipeline and Cash Runway Support Unchanged $82 Price Target and Buy Rating
Morgan Stanley Analyst forecast on CRSP
Terence Flynn
Morgan Stanley
Morgan Stanley
$60
Hold
28.92%
Upside
Reiterated
08/04/26
Morgan Stanley Sticks to Their Hold Rating for Crispr Therapeutics AG (CRSP)
Piper Sandler Analyst forecast on CRSP
Edward Tenthoff
Piper Sandler
Piper Sandler
$110
Buy
136.36%
Upside
Reiterated
08/04/26
Piper Sandler Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)
TD Cowen Analyst forecast on CRSP
Tyler Van Buren
TD Cowen
TD Cowen
$45
Hold
-3.31%
Downside
Reiterated
08/03/26
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (NASDAQ: CRSP), Supernus Pharmaceuticals (NASDAQ: SUPN) and Krystal Biotech (NASDAQ: KRYS)
Citi Analyst forecast on CRSP
Yigal Nochomovitz
Citi
Citi
$82→$88
Buy
89.08%
Upside
Reiterated
08/03/26
Casgevy Momentum and Pipeline Catalysts Drive Yigal Nochomovitz to Maintain Buy Rating and Raise Price Target to $88
RBC Capital Analyst forecast on CRSP
Luca Issi
RBC Capital
RBC Capital
$50
Hold
7.43%
Upside
Reiterated
08/03/26
RBC Capital Keeps Their Hold Rating on Crispr Therapeutics AG (CRSP)
Citizens JMP Analyst forecast on CRSP
Silvan Turkcan
Citizens JMP
Citizens JMP
$80
Buy
71.90%
Upside
Reiterated
07/22/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Crispr Therapeutics AG (NASDAQ: CRSP) and GlaxoSmithKline (LSE: GB:GSK)
Mizuho Securities Analyst forecast on CRSP
Unknown Analyst
Mizuho Securities
Not Ranked
Mizuho Securities
$85
Buy
82.64%
Upside
Reiterated
06/10/26
Crispr Therapeutics AG (CRSP) Gets a Buy from Mizuho Securities
Bernstein Analyst forecast on CRSP
William Pickering
Bernstein
Bernstein
$50→$56
Hold
20.33%
Upside
Assigned
05/13/26
Crispr Therapeutics price target raised to $56 from $50 at BernsteinCrispr Therapeutics price target raised to $56 from $50 at Bernstein
Evercore ISI Analyst forecast on CRSP
Jonathan Miller
Evercore ISI
Evercore ISI
$74→$76
Buy
63.30%
Upside
Reiterated
05/11/26
Crispr Therapeutics price target raised to $76 from $74 at Evercore ISICrispr Therapeutics price target raised to $76 from $74 at Evercore ISI
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Crispr Therapeutics AG

3 Months
Mani ForooharLeerink Partners
Success Rate
13/22 ratings generated profit
59%
Average Return
+7.56%
Copying Mani Foroohar's trades and holding each position for 3 Months would result in 59.09% of your transactions generating a profit, with an average return of +7.56% per trade.
1 Year
Mani ForooharLeerink Partners
Success Rate
11/22 ratings generated profit
50%
Average Return
+7.21%
Copying Mani Foroohar's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +7.21% per trade.
2 Years
Mani ForooharLeerink Partners
Success Rate
11/22 ratings generated profit
50%
Average Return
+0.33%
Copying Mani Foroohar's trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +0.33% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CRSP Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
9
9
9
9
9
Buy
6
6
6
7
4
Hold
3
5
5
6
7
Sell
1
0
0
0
0
Strong Sell
0
0
0
0
0
total
19
20
20
22
20
In the current month, CRSP has received 13 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. CRSP average Analyst price target in the past 3 months is 73.14.
Each month's total comprises the sum of three months' worth of ratings.

CRSP Financial Forecast

CRSP Earnings Forecast

Next quarter’s earnings estimate for CRSP is -$1.06 with a range of -$1.50 to -$0.46. The previous quarter’s EPS was -$0.94. CRSP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 37.50% of the time in the same period. In the last calendar year CRSP has Performed in-line its overall industry.
Next quarter’s earnings estimate for CRSP is -$1.06 with a range of -$1.50 to -$0.46. The previous quarter’s EPS was -$0.94. CRSP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 37.50% of the time in the same period. In the last calendar year CRSP has Performed in-line its overall industry.

CRSP Sales Forecast

Next quarter’s sales forecast for CRSP is $14.06M with a range of $0.00 to $77.25M. The previous quarter’s sales results were $10.18M. CRSP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.91% of the time in the same period. In the last calendar year CRSP has Performed in-line its overall industry.
Next quarter’s sales forecast for CRSP is $14.06M with a range of $0.00 to $77.25M. The previous quarter’s sales results were $10.18M. CRSP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.91% of the time in the same period. In the last calendar year CRSP has Performed in-line its overall industry.

CRSP Stock Forecast FAQ

What is CRSP’s average 12-month price target, according to analysts?
Based on analyst ratings, Crispr Therapeutics’s 12-month average price target is 73.14.
    What is CRSP’s upside potential, based on the analysts’ average price target?
    Crispr Therapeutics has 57.16% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CRSP a Buy, Sell or Hold?
          Crispr Therapeutics has a consensus rating of Moderate Buy which is based on 9 buy ratings, 6 hold ratings and 0 sell ratings.
            What is Crispr Therapeutics’s price target?
            The average price target for Crispr Therapeutics is 73.14. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $110.00 ,the lowest forecast is $45.00. The average price target represents 57.16% Increase from the current price of $46.54.
              What do analysts say about Crispr Therapeutics?
              Crispr Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.
                How can I buy shares of CRSP?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.